SCHEMBL25037372

SCHEMBL25037372

CCc1c(N2CCN(C(=O)OC(C)(C)C)CC2)c(=O)n2nc(C3=CCOCC3)nc2n1CC(=O)O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ WRN Q14191 1/20 0.51
▸ ABCB1 P08183 1/20 0.34
▸ ABCG2 Q9UNQ0 1/20 0.34
▸ ADORA2A P29274 2/20 0.34
▸ ADORA1 P30542 1/20 0.34
▸ TBK1 Q9UHD2 1/20 0.33
▸ CKS1B P61024 2/20 0.33
▸ SKP1 P63208 2/20 0.33
▸ SKP2 Q13309 2/20 0.33
▸ ADORA3 P0DMS8 1/20 0.32
▸ GBA1 P04062 2/20 0.32
▸ ACKR3 P25106 2/20 0.32
▸ PIK3CA P42336 2/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ MAPT P10636 1/20 0.31
▸ ESR2 Q92731 1/20 0.31
▸ ACHE P22303 1/20 0.31
▸ PIK3CD O00329 1/20 0.31
▸ DDB1 Q16531 1/20 0.30
▸ CRBN Q96SW2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30038124 0.97 WRN (0.49) WRNABCB1ABCG2ADORA2AADORA1
SCHEMBL25035229 0.94 WRN (0.51) WRNABCB1ABCG2ADORA2AADORA1
SCHEMBL31394663 0.92 WRN (0.51) WRNABCB1ABCG2ADORA2AADORA1
SCHEMBL25036834 0.91 WRN (0.43) WRNABCB1ABCG2ADORA2AADORA1
SCHEMBL30039086 0.90 WRN (0.48) WRNABCB1ABCG2ADORA2AADORA1
SCHEMBL30038680 0.88 WRN (0.42) WRNABCB1ABCG2ADORA2AADORA1
SCHEMBL30038143 0.88 WRN (0.46) WRNABCB1ABCG2ADORA2AADORA1
SCHEMBL25035182 0.86 WRN (0.61) WRNTBK1ALDH1A1MAPTESR2
SCHEMBL31590577 0.85 WRN (0.54) WRNPIK3CAALDH1A1MAPTESR2
SCHEMBL25037086 0.85 WRN (0.65) WRNTBK1ALDH1A1MAPTESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4619104-A1 BICYCLIC HETEROCYCLES AND THEIR USE AS WRN INHIBITORS Novartis AG (CH) 2025-09-24 — — EP disclosed
WO-2025049746-A1 COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME EIKON THERAPEUTICS, INC. (US) 2025-03-06 — — WO disclosed
WO-2025021148-A1 WRN INHIBITOR, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF 贝达药业股份有限公司 2025-01-30 — — WO disclosed
US-20240360118-A1 Bicyclic Compounds and their Uses NOVARTIS PHARMA AG (CH) 2024-10-31 — — US disclosed
WO-2024105553-A1 BICYCLIC HETEROCYCLES AND THEIR USE AS WRN INHIBITORS NOVARTIS AG (CH) 2024-05-23 — — WO disclosed
EP-4347596-A1 TRIAZOLO-PYRIMIDINE ANALOGUES FOR TREATING DISEASES CONNECTED TO THE INHIBITON OF WERNER SYNDROME RECQ HELICASE (WRN) Novartis AG (CH) 2024-04-10 — — EP disclosed
US-20230046859-A1 Bicyclic Compounds and their Uses NOVARTIS PHARMA AG (CH) 2023-02-16 — — US disclosed
WO-2022249060-A1 TRIAZOLO-PYRIMIDINE ANALOGUES FOR TREATING DISEASES CONNECTED TO THE INHIBITON OF WERNER SYNDROME RECQ HELICASE (WRN) NOVARTIS AG (CH) 2022-12-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240360118-A1 Bicyclic Compounds and their Uses H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 WRN 1829/4885ABCB1 58/4885ABCG2 54/4885
US-20230046859-A1 Bicyclic Compounds and their Uses H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, C1R, F12 WRN 1829/4885ABCB1 58/4885ABCG2 54/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback